Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.
Moderna Inc. MRNA, -0.22% said Wednesday that it expects to resolve supply issues for its new COVID-19 booster “in the coming days.”
Analysts remain very bullish about these former big winners.
Moderna Inc (NASDAQ: MRNA) has taken a big hit over the past seven weeks, which, as per an Oppenheimer analyst, is a fantastic opportunity for the long-term investors. Reasons to own the Moderna stock
Hartaj Singh, Oppenheimer analyst, joins 'Squawk on the Street' to discuss how to play the biotech sector and more.

Is Moderna a Post-Pandemic Buy?

06:00am, Tuesday, 20'th Sep 2022
Moderna is ready for a post-pandemic world.

Vaccine Stocks: Down but Not Out?

06:29pm, Monday, 19'th Sep 2022
Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.

Why Moderna Stock Dropped Today

06:01pm, Monday, 19'th Sep 2022
President Biden's comments weighed on the biotech's shares.
Jefferies analyst Michael Yee joins 'Closing Bell' to discuss biotech and pharmaceutical stocks and how President Biden's comments yesterday that the pandemic is over are impacting those stocks.
Yahoo Finance anchors Dave Briggs, Seana Smith and Rachelle Akuffo report on Moderna and other COVID vaccine stocks dropping after President Biden hints at a potential end to the pandemic.
It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.
"The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.
Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell
BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

03:54pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE